Kingsoft Cloud (NASDAQ:KC) vs. Portage Biotech (NASDAQ:ALP) Critical Survey

Kingsoft Cloud (NASDAQ:KC) and Portage Biotech (NASDAQ:ALP) are both technology companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Institutional & Insider Ownership

13.4% of Kingsoft Cloud shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 14.2% of Kingsoft Cloud shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Kingsoft Cloud and Portage Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kingsoft Cloud	-5.49%	-7.85%	-2.41%
Portage Biotech	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for Kingsoft Cloud and Portage Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kingsoft Cloud	1	0	4	1	2.83
Portage Biotech	1	2	0	0	1.67

Kingsoft Cloud presently has a consensus target price of $16.67, indicating a potential upside of 103.33%. Portage Biotech has a consensus target price of $12.50, indicating a potential upside of 274.25%. Given Portage Biotech’s higher probable upside, analysts clearly believe Portage Biotech is more favorable than Kingsoft Cloud.

Risk & Volatility

Kingsoft Cloud has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Earnings and Valuation

This table compares Kingsoft Cloud and Portage Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kingsoft Cloud	$1.37 billion	1.81	-$133.88 million	($0.28)	-29.27
Portage Biotech	$100,000.00	51.77	-$38.63 million	($409.00)	-0.01

Portage Biotech has lower revenue, but higher earnings than Kingsoft Cloud. Kingsoft Cloud is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Kingsoft Cloud beats Portage Biotech on 8 of the 15 factors compared between the two stocks.

About Kingsoft Cloud

Kingsoft Cloud Holdings Limited provides cloud services to businesses and organizations primarily in China. The company's products portfolio includes cloud products, including infrastructure as a service (IaaS) infrastructure, platform as a service (PaaS) middleware, and software as a service (SaaS) applications that primarily consist of cloud computing, network, database, big data, security, storage, and delivery solutions. It offers research and development services, as well as enterprise digital solutions and related services. The company also provides public cloud services to customers in various verticals, including video, e-commerce, intelligent mobility, artificial intelligence, and mobile internet; and enterprise cloud services to customers in financial services, public service, and healthcare businesses. Kingsoft Cloud Holdings Limited was incorporated in 2012 and is headquartered in Beijing, the People's Republic of China.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.